Urotensin II immunoreactivity in the human circulation: Evidence for widespread tissue release

Clinical Chemistry

Volumn 55, Issue 11, 2009, Pages 2040-2048

  Chen, Yen Hsing ^a   Yandle, Timothy G ^a   Richards, A Mark ^a   Palmer, Suetonia C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

UROTENSIN II; OXYGEN; UROTENSIN;

ACUTE CORONARY SYNDROME; ADULT; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR DISEASE; CIRCULATION; FEMALE; FEMORAL ARTERY; HEART CATHETERIZATION; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; BLOOD PRESSURE; IMMUNOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ACUTE CORONARY SYNDROME; AGED; BLOOD CIRCULATION; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXYGEN; UROTENSINS;

EID: 70449727914     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.131748     Document Type: Article

References (37)

1. Pearson D, Shively JE, Clark BR, Geschwind, II, Barkley M, Nishioka RS, Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A 1980;77:5021-5024 (Pubitemid 11236553)
2. Gibson A, Wallace P, Bern HA. Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen Comp Endocrinol 1986;64:435-439 (Pubitemid 17202473)
3. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-286 (Pubitemid 129515542)
4. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirik A, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001;280:H925-8.
5. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003; 93:246-253 (Pubitemid 36993236)
6. Bousette N, Pottinger J, Ramli W, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 2006;27:2919-2926 (Pubitemid 44584417)
7. Gruson D, Rousseau MF, Ahn SA, van Linden F, Ketelslegers JM. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 2006;27:1527-1531 (Pubitemid 44236010)
8. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002;106:2877-2880 (Pubitemid 35424734)
9. Richards AM, Nicholls MG, Lainchbury JG, Fisher S, Yandle TG. Plasma urotensin II in heart failure. Lancet 2002;360:545-546
10. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359:1990-1997 (Pubitemid 34663713)
11. Khan SQ, Bhandari SS, Quinn P, Davies JE, Ng LL. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007;117: 323-328 (Pubitemid 46507623)
12. Dschietzig T, Bartsch C, Pregla R, Zurbrugg HR, Armbruster FP, Richter C, et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 2002;110:33-38 (Pubitemid 35435330)
13. Russell FD, Meyers D, Galbraith AJ, Bett N, Toth I, Kearns P, Molenaar P. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003;285:H1576-81.
14. Brandt PW, Partridge JB, Wattie WJ. Coronary arteriography: method of presentation of the arteriogram report and a scoring system. Clin Radiol 1977;28:361-365
15. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367
16. Guyton AC, Hall JE. Textbook of medical physiology. 9th ed. Philadelphia: W.B. Saunders; 1996.
17. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000;131:1262-1274
18. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004;22:1341-1344 (Pubitemid 38888080)
19. Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007; 20:211-217 (Pubitemid 46150023)
20. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003;104:1-5. (Pubitemid 36249917)
21. Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, Roberts S. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. Liver Int 2007;27: 1232-1239 (Pubitemid 47543152)
22. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P, Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 2006;69: 1253-1258
23. Elshourbagy NA, Douglas SA, Shabon U, Harrison S, Duddy G, Sechler JL, et al. Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002;136:9-22. (Pubitemid 34499311)
24. Maguire JJ, Kuc RE, Wiley KE, Kleinz MJ, Davenport AP. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 2004;25:1767-1774
25. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 1998;95:15803-15808 (Pubitemid 29018781)
26. Nothacker HP, Wang Z, McNeill AM, Saito Y, Merten S, O'Dowd B, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol 1999;1:383-385 (Pubitemid 129493582)
27. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001;19:2185-2190 (Pubitemid 33135240)
28. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004; 176:117-123 (Pubitemid 39078653)
29. Joyal D, Huynh T, Aiyar N, Guida B, Douglas S, Giaid A. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 2006;108:31-35 (Pubitemid 43324903)
30. Onan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 2004;18:2344-2354 (Pubitemid 39215262)
31. Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006;41:285-295 (Pubitemid 44080219)
32. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 2002;37:767-772 (Pubitemid 35404215)
33. Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. J Nephrol 2005;18:727-732 (Pubitemid 43085439)
34. Mallamaci F, Cutrupi S, Pizzini P, Tripepi G, Zoccali C. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 2006;19:505-510
35. Bullock RE, Am HA, Simpson I, Ward MK, Hall RJ. Cardiac abnormalities and exercise tolerance in patients receiving renal replacement therapy. Br Med J (Clin Res Ed) 1984;289:1479-1484 (Pubitemid 15219270)
36. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Pizzini P, Cutrupi S, Malatino L. Urotensin II and cardiomyopathy in end-stage renal disease. Hypertension 2008;51:326-333
37. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 2005;26:2211-2214